But not everything is expected to change at the Gaithersburg campus.
Nuventra Pharma Sciences, a clinical pharmacology and PK/PD consultancy in Durham, NC, recently offered some insights on why clinical trials fail. In addition to biological considerations—such as pharmacokinetics, pharmacodynamic, and human response to a drug varying from animal models—Nuventra presented a list of reasons that included:
Over the past couple of years, the term “record-breaking” has frequently been used to describe the state of venture capital in the US, as the space hits new heights with deal value, mega-rounds and fundraising. In 2018, some of these records reached heights not seen since the dot-com boom.
Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.
The National Institute of Health awarded a University of Maryland research center team of scientists $3.6 million to help fund their work on the cells responsible for destroying cancer cells.
Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent.
A team of researchers led by the Johns Hopkins University of Medicine has developed a methylated epigenetic biomarker panel integrating a sponge-based collection tool and a methylated-bead PCR method that it believes can detect Barrett’s esophagus (BE).
The life sciences industry is taking off, with the medical technology and biotech sectors expected to grow further as traditional pharmaceutical companies are joined by startups and incubator labs driving new research and development. And with life sciences innovation rising, so is demand for the space in which to innovate.
Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review, please email BHI an updated vita by this Thursday, February 14th.
YOU THOUGHT SHARK TANK WAS TOUGH?
NOW ACCEPTING APPLICATIONS at
https://form.jotform.com/90276838255163
Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!
APPLICATION DEADLINE: March 8, 2019
FINALISTS ANNOUNCED: March 21, 2019
PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019
Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.
Distinguished Judges:
- Moderator – Rich Bendis, President and CEO, BioHealth Innovation
- 2019 Judges
- John Rubin, Executive Director, JP Morgan Private Bank
- Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
- Raghav Bhargava, Associate, New Enterprise Associates (NEA)
- Ethel Rubin, NIH Entrepreneur in Residence
- Representative from AstraZeneca
PRIZES
Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges
CRITERIA
Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection
PRIZES
Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges